Horizon 2020 grant for Jaap Deinum and Henri Timmers

Horizon 2020[1]

Jaap Deinum (photo l) and Henri Timmers (photo r) of the Dept. of Internal Medicine (sections of vascular medicine and endocrinology) serve as internists and clinical investigators within the Radboud Adrenal Centre. They take part in the 'vascular damage' research theme. As a collaborative effort, they formed a consortium called 'European Network for the Study of Adrenal Tumors - Hypertension' (www.ensat.org). 

With this consortium they obtained a € 7.6 million Horizon 2020 grant (PHC 5-2014 call: Health promotion and disease prevention: translating 'omics' into stratified approaches). Nearly € 700k is available for their studies at the Radboudumc. The project is entitled 'Application of omics-based strategies for improved diagnosis and treatment of endocrine hypertension'. 

Timmers , HenriSynopsis of the project:Deinum , Jaap
Arterial hypertension affects up to 45% of the general population and is responsible for 7.1 million deaths per year worldwide. Although a large therapeutic arsenal exists, blood pressure control is sub-optimal in up to two thirds of patients. Detection of secondary forms of hypertension is key to targeted management of the underlying disease and prevention of cardiovascular complications. Endocrine forms of hypertension include a group of adrenal disorders resulting in increased production of hormones affecting blood pressure regulation: primary aldosteronism, pheochromocytoma/functional paraganglioma and Cushing's syndrome. These diseases are associated with increased cardiovascular and metabolic risk and with diminished quality of life. This project will develop and evaluate an omics-based stratified health promotion program for patients with endocrine forms of hypertension. Specific omics profiles for patients with different forms of adrenal hypertension will be established by integrating high throughput genetics, genomics and metabolomics data with phenome annotations through bioinformatics modelling. Established profiles will be validated as stratification biomarkers and applied to the screening of referred hypertensive patients for both stratifying primary forms of hypertension for effective and cost efficient therapy as well as improving identification of endocrine causes for curative treatment and prevention of cardiovascular and metabolic complications.


<< back to overview news items